Consensus Mersana Therapeutics, Inc.

Equities

MRSN

US59045L1061

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
2.85 ^USD	-1.04%		-14.67%	+22.84%

Mar. 20	North American Morning Briefing : Markets on Hold -2-	DJ
Mar. 19	JPMorgan Upgrades Mersana Therapeutics to Neutral From Underweight, Price Target is $5	MT

Evolution of the average Target Price on Mersana Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

586fcc764c0e5c04347.UjUdbw82VTLmbZ90_T7Ywmgxx_ty4CJk-X0nkS7mQxc.GWFUJEhBLwOcAfFNtGqBlyNThq42rksBnjNj1B2xNUImUk9eZAQ5St8B9A~5da1a3262b1c51d9d88742561f1ff763

Analyst Recommendations on Mersana Therapeutics, Inc.

JPMorgan Upgrades Mersana Therapeutics to Neutral From Underweight, Price Target is $5	Mar. 19	MT
Truist Securities Upgrades Mersana Therapeutics to Buy From Hold, Price Target is $9	Feb. 29	MT
Guggenheim Upgrades Mersana Therapeutics to Buy From Neutral, Price Target is $7	Feb. 29	MT
Wedbush Upgrades Mersana Therapeutics to Outperform From Neutral, Notes Increased Confidence in Program; Adjusts PT to $7 From $2	Feb. 29	MT
Citigroup Upgrades Mersana Therapeutics to Buy From Neutral, Raises Price Target to $5 From $1	Dec. 04	MT
Baird Downgrades Mersana Therapeutics to Neutral From Outperform, Adjusts Price Target to $1 From $7	23-07-28	MT
SVB Securities Lowers Mersana Therapeutics Price Target to $4 From $15, Outperform Rating Maintained	23-07-27	MT
Guggenheim Downgrades Mersana Therapeutics to Neutral From Buy	23-07-27	MT
JPMorgan Downgrades Mersana Therapeutics to Underweight From Neutral	23-07-27	MT
Citigroup Downgrades Mersana Therapeutics to Neutral From Buy, Cuts Price Target to $1 From $10	23-07-27	MT
Wedbush Downgrades Mersana Therapeutics to Neutral From Outperform, Adjusts Price Target to $2 From $12	23-07-27	MT
Truist Securities Downgrades Mersana Therapeutics to Hold From Buy	23-07-27	MT
Citigroup Adjusts Price Target on Mersana Therapeutics to $10 From $15, Keeps Buy Rating	23-06-16	MT
JPMorgan Downgrades Mersana Therapeutics to Neutral From Overweight, Adjusts Price Target to $5 From $11	23-06-16	MT
Wedbush Cuts PT on Mersana Therapeutics to $12 From $17 After US FDA Places Partial Hold on Cancer Drug UpRi Trials; Keeps Outperform Rating	23-06-15	MT
Wedbush Adjusts Price Target on Mersana Therapeutics to $12 From $17, Maintains Outperform Rating	23-06-15	MT
Guggenheim Initiates Mersana Therapeutics With Buy Rating, $14 Price Target	23-06-15	MT
Citigroup Adjusts Price Target on Mersana Therapeutics to $15 From $12, Maintains Buy Rating	23-05-11	MT
JPMorgan Upgrades Mersana Therapeutics to Overweight From Neutral, Price Target is $10	23-03-16	MT
Truist Securities Adjusts Price Target on Mersana Therapeutics to $10 From $8, Maintains Neutral Rating	22-11-21	MT
Wedbush Lifts Price Target on Mersana Therapeutics to $17 From $16, Keeps Outperform Rating	22-10-24	MT
Baird Raises Mersana Therapeutics Price Target to $20 From $18, Maintains Outperform Rating	22-08-09	MT
Wedbush Adjusts Price Target on Mersana Therapeutics to $16 From $14, Keeps Outperform Rating	22-08-09	MT
Baird Adjusts Mersana Therapeutics' Price Target to $18 From $23, Keeps Outperform Rating	22-05-10	MT
Wedbush Adjusts Mersana Therapeutics Price Target to $14 From $18, Maintains Outperform Rating	22-05-09	MT